Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/215

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/003332PLANT-BASED COVID-19 VARIANT RECOMBINANT SPIKE PROTEIN EXPRESSION VECTOR AND RECOMBINANT PROTEIN USING SAME
WO 26.01.2023
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No PCT/KR2022/010552 Applicant BIOAPPLICATIONS INC. Inventor SOHN, Eun-Ju
The present invention relates to a plant-based COVID-19 variant recombinant spike protein expression vector, and a recombinant protein using the expression vector, wherein a plant expression system is used such that the recombinant protein does not have the disadvantages of animal-derived recombinant proteins and exhibits an excellent SARS coronavirus 2 prevention and treatment effect, and thus can be effectively utilized as a safe composition for preventing and treating COVID-19.
2.WO/2023/002433COMPOSITIONS AND VACCINES FOR TREATING AND/OR PREVENTING CORONAVIRUS VARIANT INFECTIONS AND METHODS OF USING THE SAME
WO 26.01.2023
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/IB2022/056759 Applicant ENGENEIC MOLECULAR DELIVERY PTY LTD Inventor BRAHMBHATT, Himanshu
The present disclosure is directed to compositions and methods useful for treating, as well as vaccinating against, SARS-CoV-2 viral infections, including SARS-CoV-2 variant viral infections.
3.WO/2023/000403SARS-COV-2 SUBPROTEIN NANO-VACCINE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
WO 26.01.2023
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2021/111511 Applicant WUHAN SHENGRUN BIOTECHNOLOGY CO., LTD. Inventor ZHENG, Junwu
A Sars-Cov-2 subprotein nano-vaccine, and a preparation method therefor and an application thereof. The nano-vaccine comprises: an organic compound self-assembled from polylactic acid, porphyrin, or a porphyrin derivative, and a Co2+ ion conjugate; Sars-Cov-2 antigen protein; a vaccine adjuvant; and a lipid. The synthetic organic compound has an adjuvant encapsulated in its core and a Sars-Cov-2 antigen protein efficiently loaded on the surface, such that a nano-vaccine system allowing for co-delivery of the Sars-Cov-2 antigen protein and vaccine adjuvant is realized, thereby maximizing the immunogenicity of the Sars-Cov-2 recombinant subprotein and enabling tracking the distribution of the subprotein in an organism by means of fluorescent molecules. In addition, the nano-vaccine is also linked with a polypeptide that can specifically target antigen-presenting cells, so as to promote the uptake of the nano-vaccine by DC cells and promote anti-viral response. The preparation method is simple and efficient and provides a way for effectively preventing Sars-Cov-2 infection.
4.WO/2023/001259PREPARATION AND APPLICATION OF RECOMBINANT MULTIVALENT NOVEL CORONAVIRUS TRIMER PROTEIN VACCINE CAPABLE OF INDUCING BROAD-SPECTRUM AND NEUTRALIZING ACTIVITY
WO 26.01.2023
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2022/107213 Applicant SINOCELLTECH LTD Inventor XIE, Liangzhi
A recombinant multivalent novel coronavirus trimer protein vaccine capable of inducing broad-spectrum and neutralizing activity. The recombinant protein component comprises, but is not limited to, a homotrimer protein formed by introducing, into an extracellular domain (ECD) of B.1.617.1 strain and B.1.617.2 strain spike (S) proteins, a mutation site and a trimerization assistance structure. The multivalent vaccine comprises an ECD trimer protein of a single component or any combination of components of the variant strains above, and a pharmaceutically acceptable adjuvant. The vaccine combination shows excellent immunogenicity in mice, and can maintain long-term humoral immunity and cellular immunity. The multivalent novel coronavirus trimer protein vaccine can be used for preventing infection-related diseases caused by infection of novel coronavirus and variant strains thereof.
5.WO/2023/002505ASSAY FOR DETECTION OF EPIDEMIOLOGICALLY IMPORTANT SARS- COV-2 VARIANTS
WO 26.01.2023
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/IN2022/050649 Applicant INDIAN COUNCIL OF MEDICAL RESEARCH Inventor NANDI, Shyam Sundar
The present invention relates to novel oligonucleotide sequences for rapid screening of epidemiologically important variants of SARS-CoV-2, wherein said oligonucleotide sequences acts as primers for amplification of sequences having Single-nucleotide polymorphisms (SNP)/mutations in the spike glycoprotein gene. The invention also relates to an assay for rapid screening of epidemiologically important variants of SARS-CoV-2 based upon using novel oligonucleotide sequences as primers. In particular, invention relates to oligonucleotide sequences of SEQ ID Nos. 1 – 37 for rapid screening of epidemiologically important variants of SARS-CoV-2.
6.WO/2023/004415SARS-COV-2 VACCINE USING BACTERIAL SPORES EXPRESSING ANTIGENIC FRAGMENTS
WO 26.01.2023
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2022/074048 Applicant UNIVERSITY OF MIAMI Inventor MIRSAEIDI, Mehdi
Disclosed are compositions comprising a SARS-CoV-2 vaccine that can be administered orally. The vaccine can be on a platform comprising a spore coat protein from a spore forming bacteria, such as Bacillus subtilis. Also disclosed are methods of preventing or treating a COVID-19 infection comprising providing the SARS-CoV-2 vaccine to a subject.
7.WO/2023/003911MUCOSAL VACCINES FOR CORONAVIRUS DISEASES
WO 26.01.2023
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/US2022/037639 Applicant LOMA LINDA UNIVERSITY Inventor LANGRIDGE, William
Compositions and methods of reducing incidence or severity of a coronavirus disease in an animal by administering, via a mucosal route, a fusion protein containing a multimeric cholera toxin B subunit and an immunogenic peptide from a coronavirus.
8.WO/2023/283669THE ORIGINS OF CORONAVIRUS, CELLS AND RECEPTORS WHICH ARE ACTIVATED BY THE VIRUS AND VACC PROTOCOL
WO 19.01.2023
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/AU2021/050741 Applicant MATIVAVARIRA, Alice Inventor MATIVAVARIRA, Alice
Coronavirus infection activates mast cells, causing them to release chemical mediators. Histamine is a major mediator which can lead to complex complications. There are 4 indirect G-protein couple receptors in a human body and ligand chloride channels in the brain and intestinal epithelium which are sensitive to histamine. Histamine can also act as a neurotransmitter and neuromodulator. The virus causes a rare condition known as systemic mastocytosis. The infection can be treated by a number of different medications which target mediators and stabilise mast cells. The virus is transmitted by a small fly that is usually found in fresh air restricted environment( poorly ventilated). Drosophila melanogaster use the same technique to attack and destroy fruits.
9.WO/2023/287324INFLUENZA VIRUS-BASED ISOLATED RECOMBINANT VIRUS
WO 19.01.2023
Int.Class C12N 15/117
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
Appl.No PCT/RU2022/050173 Applicant JOINT STOCK COMPANY "BIOCAD" Inventor RUDENKO, Larisa Georgievna
The present invention relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated nucleic acid encoding a recombinant polypeptide for increasing the titer of antibodies to influenza virus (variants), an influenza virus-based recombinant virus for inducing specific immunity to influenza virus and/or preventing influenza virus-related diseases, a pharmaceutical composition and a vaccine that include the above influenza virus-based recombinant virus, as well as their use for inducing specific immunity to influenza virus and/or preventing influenza virus-related diseases.
10.20230015616CORONAVIRUS VACCINES AND USES THEREOF
US 19.01.2023
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17437266 Applicant ARGORNA PHARMACEUTICALS LTD Inventor Bill Biliang ZHANG

This disclosure relates to coronavirus vaccines and uses thereof. In one aspect, the disclosure provides a nucleic acid vaccine, comprising a sequence encoding a spike protein or fragment thereof derived from a coronavirus.